Exciting results from ARGO trial: -Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA. -Met primary endpoint of ACR50 at week 12 vs PBO. -62% achieved MDA -48% achieved composite of ACR 70+PASI 100 Looking forward to phase 3 results!!! Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS

Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort -Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated. -In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5

So much needed in SLE and pregnancy 1. Risk stratification at diagnosis 2. Pregnancy counseling at dx and >1 y before pregnancy 3. Close collab with GYN necessary 4. Challenging management given gaps in evidence. #EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452

Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE

SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks: •Early TNFi: 3.7 •Combo csDMARDs: 4.1 •Step-up csDMARDs: 4.7 Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2

Precision immunotherapy in axial spondyloarthritis: TRBV9xCD3 bispecific antibodies selectively depleted autoreactive TRBV9+ T cells from HLA-B27+ AS patient samples while sparing over 95 percent of the T cell repertoire. TRBV9xCD3 bispecific antibodies selectively depleted https://t.co/8UXqEaDYnS

In vitro, balinatunfib (TNFR1-selective inhibitor) preserved Treg expansion in CD4+ T cells co-cultured with IL-2 and memTNF (Treg 8.99 percent, p<0.0001), unlike adalimumab and etanercept which reduced Tregs by 27.5 to 41 percent. Confirms TNFR2 sparing with selective TNFR1 https://t.co/xaczz87Xrd

Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8